iStock.com/whyframestudio

A recent study aimed to “evaluate long-term survival trends over the past 25 years” in patients with extensive-stage small-cell lung cancer (ES-SCLC).

A team of researchers from Japan conducted the study and published their findings in Thoracic Cancer.

Investigators explained that “therapeutic progress” for ES-SCLC has been limited. Despite the introduction of immune checkpoint inhibitors (ICIs), real-world evidence on the impact of ICIs on survival “remains uncertain.”

Eligible patients included those diagnosed with ES-SCLC who were treated at a Japanese cancer center between April 1999 and March 2023. Investigators retrospectively reviewed patient data and categorized individual cases by diagnosis period. Diagnosis periods included period A from 1999 to 2003, period B from 2004 to 2008, period C from 2009 to 2013, period D from 2014 to 2018, and period E from 2019 to 2023.

Investigators measured overall survival (OS) from diagnosis to time of death and used Kaplan-Meier and log-rank tests, as well as multivariable Cox models, to record those measurements. They also performed subgroup analyses of data for patients aged 75 years and older, patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher, and patients with brain metastases.

For the 452 cases that were retrospectively reviewed, the median OS across diagnosis periods was 9.8 months, 12.5 months, 13.4 months, 11.8 months, and 13.6 months in periods A through E, respectively. Furthermore, investigators highlighted that the 2-year OS rates across the same periods were 6.2%, 18.2%, 18.6%, 17.3%, and 28.9%, respectively.

The multivariable analysis illustrated various subgroups that were “independently associated with OS,” including patients with an ECOG performance status of 2 or higher (hazard ratio [HR], 1.51) receipt of first-line therapy (HR, 0.09), and ICI exposure (HR, 0.73, P=0.013).

Investigators also explained the implications of the results among patients who received systemic therapy and found that exposure to ICI therapy “was associated with longer OS (15.2 vs. 12.3 months; 2-year OS 32.1% vs. 15.9%; p < 0.005).”

Furthermore, in the subgroups of patients aged  75 years and older, performance status of 2 or higher, and brain metastases, “ICI-associated HRs” were 0.67, 0.69, and 0.63, respectively.

In reflecting on the findings, investigators explained, “Collectively, these findings suggest that the inclusion of ICIs in real-world practice has contributed to improved outcomes in ES-SCLC.”

“Real-world survival in ES-SCLC improved over 25 years,” they concluded. “ICI exposure was independently associated with improved OS, as well as in clinically high-risk subgroups.”